Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial - XML Representation

Raw xml | Download

<Evidence xmlns="http://hl7.org/fhir">
  <id value="179635"/>
  <meta>
    <versionId value="7"/>
    <lastUpdated value="2024-12-13T21:07:33.593Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
  </text>
  <url value="https://fevir.net/resources/Evidence/179635"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/179635"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial"/>
  <title
         value="ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <author>
    <name value="Brian S. Alper"/>
  </author>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ComparativeParticipantFlowEvidence"/>
        <display value="ComparativeParticipantFlowEvidence"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <relatedArtifact>
    <type value="cite-as"/>
    <citation
              value="ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json."/>
  </relatedArtifact>
  <relatedArtifact>
    <type value="derived-from"/>
    <resourceReference>🔗 
      <reference value="Citation/179637"/>
      <type value="Citation"/>
      <display
               value="18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"/>
    </resourceReference>
  </relatedArtifact>
  <description
               value="Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial"/>
  <variableDefinition>
    <description value="Participants in the opioid detoxification trial"/>
    <variableRole value="population"/>
  </variableDefinition>
  <variableDefinition>
    <description value="GroupAssignment: Lofexidine vs. Placebo"/>
    <variableRole value="exposure"/>
    <comparatorCategory value="false"/>
  </variableDefinition>
  <variableDefinition>
    <description value="Dropout due to stopping intervention"/>
    <variableRole value="outcome"/>
    <observed>🔗 
      <reference value="EvidenceVariable/179636"/>
      <type value="EvidenceVariable"/>
      <display
               value="PartiicipantFlowMeasure: Dropout due to stopping intervention"/>
    </observed>
  </variableDefinition>
  <statistic>
    <description
                 value="18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p &lt; 0.01)"/>
    <statisticType>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/181513"/>
        <code value="STATO:0000245"/>
        <display value="Risk Ratio"/>
      </coding>
    </statisticType>
    <quantity>
      <value value="1.59"/>
    </quantity>
    <numberAffected value="30"/>
    <sampleSize>
      <numberOfParticipants value="68"/>
    </sampleSize>
    <attributeEstimate>
      <description value="p &lt; 0.01"/>
      <type>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/181513"/>
          <code value="STATO:0000700"/>
          <display value="p-value"/>
        </coding>
      </type>
      <quantity>
        <value value="0.01"/>
        <comparator value="&lt;"/>
      </quantity>
    </attributeEstimate>
  </statistic>
</Evidence>